This database contains 67 studies, archived under the term: "mental status schedule"
Click here to filter this large number of results.
Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial
Cukierman-Yaffe, Tali,
Gerstein, Hertzel C.,
Williamson, Jeff D.,
Lazar, Ronald M.,
Lovato, Laura,
Miller, Michael E.,
Coker, Laura H.,
Murray, Anne,
Sullivan, Mark D.,
Marcovina, Santica M.,
Launer, Lenore J.
Objective: Diabetes is associated with cognitive decline and dementia. However, the relationship between the degree of hyperglycemia and cognitive status remains unclear. This was explored using baseline cognitive measures collected in the ongoing Memory in Diabetes (MIND) substudy of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.; Research Design and Methods: The relationship […]
Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice
Hayashi, Yoshihito,
Ishida, Yasushi,
Inoue, Teruhiko,
Udagawa, Mitsutaka,
Takeuchi, Kouzou,
Yoshimuta, Hirofumi,
Kiue, Kouichirou,
Ninomiya, Yoshimasa,
Kawano, Jiro,
Sameshima, Tetsuro,
Kawahara, Takashi,
Goto, Isamu,
Shudo, Kenji,
Kurayama, Shigeki,
Nakamura, Jungo,
Okahara, Kazunori,
Mitsuyama, Yoshio
The efficacy and safety of the kampo medicine Yokukansan (YKS, TJ-54) in the treatment of behavioral and psychological symptoms of dementia (BPSD) were investigated in patients with Alzheimer’s disease (AD) in an open-label study. This study included 26 patients who had been diagnosed as having AD and were not treated with donepezil hydrochloride. These patients […]
The social treatment: the benefits of group interventions in residential care settings
Haslam, Catherine,
Haslam, S. Alexander,
Jetten, Jolanda,
Bevins, Adam,
Ravenscroft, Sophie,
Tonks, James
We report findings from an intervention study that investigates the impact of group reminiscence (GR) and individual reminiscence (IR) activities on older adults living in care settings. This research aimed to provide a theory-driven evaluation of reminiscence based on a social identity framework. This framework predicts better health outcomes for group-based interventions as a result […]
Effects of rivastigmine in Alzheimer’s disease patients with and without hallucinations
Cummings, Jeffrey,
Emre, Murat,
Aarsland, Dag,
Tekin, Sibel,
Dronamraju, Nalina,
Lane, Roger
Hallucinations in Alzheimer’s disease (AD) may indicate greater cortical cholinergic deficits. Rivastigmine has shown larger treatment benefits versus placebo in dementia with Lewy bodies and Parkinson’s disease dementia patients with hallucinations. In this retrospective, hypothesis-generating analysis, we investigated whether hallucinations in AD were associated with greater treatment benefits with rivastigmine. Data were pooled from two […]
Therapeutic conversation to improve mood in nursing home residents with Alzheimer’s disease
Few studies have tested strategies to address the mental health needs of individuals with Alzheimer’s disease (AD). To test a newly developed, empirically based modified counseling approach, 30 nursing home residents with AD were randomly assigned to a modified counseling (Therapeutic Conversation) treatment group or usual care control group. Mini-Mental State Examination mean scores were […]
Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia
Schmidt, Reinhold,
Alf, Claude,
Bancher, Christian,
Benke, Thomas,
Berek, Klaus,
Dal-Bianco, Peter,
Führwürth, Gerhard,
Imarhiagbe, Douglas,
Jagsch, Christian,
Lechner, Anita,
Rainer, Michael,
Reisecker, Franz,
Rotaru, Juliana,
Uranüs, Margarete,
Walter, Andreas,
Winkler, Andreas,
Wuschitz, Albert
We performed a 6-month open-label study on the use of the transdermal rivastigmine patch in clinical routine in 103 patients with Alzheimer’s disease from 25 outpatient services in Austria. After baseline, safety and tolerability of the 10 cm2–rivastigmine patch was assessed at week 4, 12 and 24 in all patients. A Mini Mental State Examination […]